Related Experiment Video
Updated: Apr 17, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
[Pre-interventional, peri-interventional and post-interventional anticoagulation in the setting of catheter ablation
M Antz1, S Willems, B A Hoffmann
1Klinik für Kardiologie, Klinikum Oldenburg, Herzzentrum, Rahel-Straus-Str. 10, 26133, Oldenburg, Deutschland, antz.matthias@klinikum-oldenburg.de.
Insights
Catheter ablation is key for atrial fibrillation treatment, alongside oral anticoagulation. This article guides peri-interventional anticoagulation strategies using direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs).
Area of Science:
- Cardiology
- Electrophysiology
Context:
- Atrial fibrillation (AF) management involves rate/rhythm control, catheter ablation, and oral anticoagulation.
- Direct oral anticoagulants (DOACs) like apixaban, dabigatran, and rivaroxaban are alternatives to vitamin K antagonists (VKAs) for AF anticoagulation.
Purpose:
- To discuss current standards and provide practical guidance for peri-interventional anticoagulation in AF catheter ablation.
- To address the evolving landscape of anticoagulation strategies around AF ablation procedures.
Summary:
- Catheter ablation is a primary treatment for atrial fibrillation (AF).
- Adequate oral anticoagulation, using either VKAs or DOACs, is crucial before, during, and after AF ablation.
- Peri-interventional anticoagulation strategies are adapting with increased DOAC use and AF ablation frequency.
Impact:
- Offers practical guidance for clinicians managing anticoagulation during AF ablation.
- Contributes to optimizing patient care and safety in AF ablation procedures.
- Highlights the dynamic nature of anticoagulation protocols in interventional cardiology.
Abstract:
In addition to treatment with drugs to control the rate and rhythm, the method of catheter ablation is a cornerstone in the treatment of atrial fibrillation. Another crucial part in treating patients with atrial fibrillation is an adequate oral anticoagulation. Apart from the vitamin K antagonists (VKA) phenprocoumon and warfarin, the direct oral anticoagulants (DOAC) apixaban, dabigatran and rivaroxaban have been approved for oral anticoagulation of patients with atrial fibrillation. As a result there are different potential treatment possibilities for pre-interventional, peri-interventional and post-interventional anticoagulation in the setting of catheter ablation for atrial fibrillation. Due to increasing clinical experience with DOAC and the increasing number of atrial fibrillation ablations worldwide, peri-interventional treatment strategies are continuously changing. Therefore, the current article discusses current standards and gives practical guidance.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Cardiac Catheterization I: Pre-Procedure Overview
Cardiac Catheterization IV: Nursing Management
Cardiac Catheterization III: Left Heart Catheterization
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

